News
GNFT
3.590
+1.13%
0.040
Weekly Report: what happened at GNFT last week (0429-0503)?
Weekly Report · 2d ago
Weekly Report: what happened at GNFT last week (0422-0426)?
Weekly Report · 04/29 09:29
Genfit S.A.: Report of foreign issuer
Press release · 04/27 10:57
GENFIT Releases Impactful CSR Performance Report
TipRanks · 04/25 21:29
Weekly Report: what happened at GNFT last week (0415-0419)?
Weekly Report · 04/22 09:27
GENFIT Announces Upcoming Shareholders Meeting
TipRanks · 04/16 01:02
Weekly Report: what happened at GNFT last week (0408-0412)?
Weekly Report · 04/15 09:24
Weekly Report: what happened at GNFT last week (0401-0405)?
Weekly Report · 04/08 09:26
Buy Rating Reiterated for Genfit SA Amidst Promising Clinical Developments and Strong Financial Outlook
TipRanks · 04/08 07:25
Kepler Capital Keeps Their Buy Rating on Genfit (GNFTF)
Justine Telliez from Kepler Capital maintained a Buy rating on Genfit (GNFTF) with a price target of €8.20. The company is a biopharmaceutical company involved in drug discovery and development for the treatment of cardiometabolic diseases. The analyst consensus on the stock is a Moderate Buy.
TipRanks · 04/07 01:45
GENFIT Releases Key Financial Documents for 2023
TipRanks · 04/05 18:27
Altice USA, Genfit, Brooge Energy among premarket losers' pack
On the Move: Altice USA, Genfit, Brooge Energy among premarket losers' pack. HWH International, ARCA biopharma, ZCMD, HWH among the biggest morning stock movers. ATUS, GNFT, BROG and HWH are among the morning's biggest losers.
Seeking Alpha · 04/05 12:29
Genfit reports FY results
Seeking Alpha · 04/05 12:28
Analysts Offer Insights on Healthcare Companies: Genfit SA (GNFT) and Laboratory (LH)
TipRanks · 04/05 12:20
Genfit Price Target Maintained With a $11.00/Share by HC Wainwright & Co.
Dow Jones · 04/05 12:20
HC Wainwright & Co. Reiterates Buy on Genfit, Maintains $11 Price Target
Benzinga · 04/05 12:10
Genfit FY23 EPS $(0.62) Down From $(0.49) YoY, Sales $41.09M Up From $27.12M YoY
Genfit reported quarterly losses of $0.62 per share. The company reported $41.09 million in sales this quarter. This is a 51.54 percent increase over sales of $27.12 million from the same period last year. Genfit also reported a 26.53 percent decrease in sales.
Benzinga · 04/04 22:03
GENFIT Announces Strong 2023 Financials and Progress
TipRanks · 04/04 21:57
Earnings Scheduled For April 4, 2024
Conagra Brands is likely to report quarterly earnings at $0.65 per share on revenue of $3.01 billion. Trinity Biotech is projected to report earnings for its fourth quarter. Other companies reporting before and after the bell include AngioDynamics and Simply Good Foods.
Benzinga · 04/04 09:18
Weekly Report: what happened at GNFT last week (0325-0329)?
Weekly Report · 04/01 09:26
More
Webull provides a variety of real-time GNFT stock news. You can receive the latest news about Genfit S.A. through multiple platforms. This information may help you make smarter investment decisions.
About GNFT
Genfit SA is a France-based biopharmaceutical company focused on the discovery and development of therapeutic and diagnostic solutions in the field of liver diseases, particularly of metabolic origin, where unmet medical needs are considerable, particularly due to a lack of approved treatments. The Company provides therapeutic and diagnostic solutions for rare and serious liver diseases , with a particular interest in diseases with largely unmet medical needs. Its laboratory capabilities include pharmacology, molecular and cellular biology, drug candidate screening, medicinal and analytical chemistry, biochemistry, omics analyses, and data science. Its in-house biobank allows to have unparalleled control and precision in the handling and preservation of biological samples, which is crucial to research. The Company leverage artificial intelligence (image processing tools and language models) to create tools that accelerate daily work and decision-making.